Table 1.

Overview of study participants.

	CTL	sMCI	cMCI	AD	Total
Number of participants	214	200	55	197	666
Age
Mean$\pm$ sd	$76.1\pm 5.1$	$76.7\pm 5.5$	$77.9\pm 7.9$	$76.6\pm 5.8$
Sex
Male	103	99	20	101	323
Female	111	101	35	96	343
MMSE score
Mean $\pm$ sd	$28.9\pm 1.1$	$27.3\pm 1.7$	$26.3\pm 1.8$	$20.0\pm 4.3$
Metabolic UHPLC-MS data obtained	172	167	45	177	561
Metabolic NMR data obtained	174	173	46	182	575
Metabolic data obtained (UHPLC-MS and NMR)	132	140	36	162	470
Genetic and metabolic UHPLC-MS data available	119	80	24	122	345
Genetic and metabolic NMR data available	120	83	23	126	352
APOE genotype available	154	155	44	174	527
APOE genotype
E3E3	84	84	13	70	251
E3E4	37	50	24	66	177
E2E3	22	10	4	9	45
E4E4	7	7	3	27	43
E2E4	3	4	0	2	9
E2E2	1	1	0	0	2

CTL normal cognition (control) participants, sMCI stable mild cognitive impairment, cMCI mild cognitive impairment converting to dementia, AD participants with Alzheimer’s disease, MMSE Mini-Mental State Examination.